Ewart Lorna, Fabre Kristin, Chakilam Ananthsrinivas, Dragan Yvonne, Duignan David B, Eswaraka Jeetu, Gan Jinping, Guzzie-Peck Peggy, Otieno Monicah, Jeong Claire G, Keller Douglas A, de Morais Sonia M, Phillips Jonathan A, Proctor William, Sura Radhakrishna, Van Vleet Terry, Watson David, Will Yvonne, Tagle Danilo, Berridge Brian
1 AstraZeneca, Cambridge CB2 0AA, UK.
2 AstraZeneca, Waltham, MA 02451, USA.
Exp Biol Med (Maywood). 2017 Oct;242(16):1579-1585. doi: 10.1177/1535370217715441. Epub 2017 Jun 16.
Tissue chips are poised to deliver a paradigm shift in drug discovery. By emulating human physiology, these chips have the potential to increase the predictive power of preclinical modeling, which in turn will move the pharmaceutical industry closer to its aspiration of clinically relevant and ultimately animal-free drug discovery. Despite the tremendous science and innovation invested in these tissue chips, significant challenges remain to be addressed to enable their routine adoption into the industrial laboratory. This article describes the main steps that need to be taken and highlights key considerations in order to transform tissue chip technology from the hands of the innovators into those of the industrial scientists. Written by scientists from 13 pharmaceutical companies and partners at the National Institutes of Health, this article uniquely captures a consensus view on the progression strategy to facilitate and accelerate the adoption of this valuable technology. It concludes that success will be delivered by a partnership approach as well as a deep understanding of the context within which these chips will actually be used. Impact statement The rapid pace of scientific innovation in the tissue chip (TC) field requires a cohesive partnership between innovators and end users. Near term uptake of these human-relevant platforms will fill gaps in current capabilities for assessing important properties of disposition, efficacy and safety liabilities. Similarly, these platforms could support mechanistic studies which aim to resolve challenges later in development (e.g. assessing the human relevance of a liability identified in animal studies). Building confidence that novel capabilities of TCs can address real world challenges while they themselves are being developed will accelerate their application in the discovery and development of innovative medicines. This article outlines a strategic roadmap to unite innovators and end users thus making implementation smooth and rapid. With the collective contributions from multiple international pharmaceutical companies and partners at National Institutes of Health, this article should serve as an invaluable resource to the multi-disciplinary field of TC development.
组织芯片有望在药物研发领域带来范式转变。通过模拟人体生理机能，这些芯片有潜力提高临床前建模的预测能力，进而使制药行业更接近其实现临床相关且最终无动物实验药物研发的目标。尽管在这些组织芯片上投入了大量科学研究与创新，但要使其在工业实验室中常规应用，仍有重大挑战有待解决。本文描述了需要采取的主要步骤，并强调了关键考量因素，以便将组织芯片技术从创新者手中转化为工业科学家手中的技术。本文由13家制药公司的科学家以及美国国立卫生研究院的合作伙伴撰写，独特地捕捉了关于促进和加速采用这项宝贵技术的进展战略的共识观点。结论是，成功将通过合作方式以及对这些芯片实际使用背景的深入理解来实现。影响声明 组织芯片（TC）领域科学创新的快速发展需要创新者和终端用户之间紧密合作。近期采用这些与人体相关的平台将填补当前在评估处置、疗效和安全性等重要特性方面能力的空白。同样，这些平台可以支持旨在解决后期研发挑战的机制研究（例如评估动物研究中发现的某种特性与人体的相关性）。在组织芯片自身研发过程中建立起其新功能能够应对现实世界挑战的信心，将加速其在创新药物研发中的应用。本文勾勒了一条将创新者和终端用户联合起来的战略路线图，从而使实施过程顺利且迅速。凭借多家国际制药公司和美国国立卫生研究院合作伙伴的共同贡献，本文应为组织芯片开发的多学科领域提供宝贵资源。
